Payment overview · 2025
General Payments
$127.59
7 reported records · 5 companies
Healthcare provider profile · identity verified
Kyle A Ward, DO
Allopathic & Osteopathic Physicians|Family Medicine · NORTON, VA · NPI 1831487222
Verified facts
What the public records show
CMS Open Payments records show Kyle A Ward, DO received $127.59 in general payments during 2025 across 7 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 32.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $41.82 | 32.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.74 | 25.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.88 | 16.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.48 | 14.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.67 | 10.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $127.59 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $41.82 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.74 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.74 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 136 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
136 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 706 | 153 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 510 | 138 |
| Levothyroxine Sodium | Levothyroxine Sodium | 498 | 102 |
| Atorvastatin Calcium | Atorvastatin Calcium | 467 | 125 |
| Lisinopril | Lisinopril | 467 | 138 |
| Losartan Potassium | Losartan Potassium | 416 | 101 |
| Omeprazole | Omeprazole | 404 | 103 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 386 | 95 |
| Metformin Hcl | Metformin Hcl | 378 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 360 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 298 | 79 |
| Montelukast Sodium | Montelukast Sodium | 260 | 62 |
| Fluticasone Propionate | Fluticasone Propionate | 259 | 77 |
| Meloxicam | Meloxicam | 250 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 243 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 242 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 239 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 227 | 62 |
| Famotidine | Famotidine | 216 | 55 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 215 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 214 | 60 |
| Furosemide | Furosemide | 213 | 59 |
| Trazodone Hcl | Trazodone Hcl | 192 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 188 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 187 | 43 |
| Carvedilol | Carvedilol | 184 | 38 |
| Potassium Chloride | Potassium Chloride | 176 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 167 | 35 |
| Simvastatin | Simvastatin | 160 | 38 |
| Eliquis | Apixaban | 159 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 159 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 158 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 152 | 29 |
| Jardiance | Empagliflozin | 141 | 25 |
| Ozempic | Semaglutide | 136 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 133 | 38 |
| Clonazepam | Clonazepam | 117 | 41 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 111 | 31 |
| Ondansetron Hcl | Ondansetron Hcl | 110 | 32 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 106 | 24 |
| Fenofibrate | Fenofibrate Nanocrystallized | 101 | 23 |
| Metformin Hcl Er | Metformin Hcl | 98 | 26 |
| Spironolactone | Spironolactone | 96 | 21 |
| Warfarin Sodium | Warfarin Sodium | 95 | 11 |
| Ibuprofen | Ibuprofen | 93 | 29 |
| Finasteride | Finasteride | 91 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 91 | 18 |
| Allopurinol | Allopurinol | 90 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 87 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 87 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 85 | 17 |
| Alprazolam | Alprazolam | 83 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 82 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 75 | 22 |
| Januvia | Sitagliptin Phosphate | 74 | 21 |
| Pregabalin | Pregabalin | 74 | 22 |
| Buspirone Hcl | Buspirone Hcl | 71 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 21 |
| Ondansetron Odt | Ondansetron | 70 | 27 |
| Sertraline Hcl | Sertraline Hcl | 69 | 18 |
| Tramadol Hcl | Tramadol Hcl | 69 | 29 |
| Prednisone | Prednisone | 68 | 32 |
| Celecoxib | Celecoxib | 66 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 15 |
| Atenolol | Atenolol | 65 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 61 | 12 |
| Cephalexin | Cephalexin | 60 | 29 |
| Propranolol Hcl | Propranolol Hcl | 59 | 11 |
| Lorazepam | Lorazepam | 58 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | 13 |
| Methocarbamol | Methocarbamol | 55 | 17 |
| Azithromycin | Azithromycin | 54 | 46 |
| Testosterone Cypionate | Testosterone Cypionate | 54 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 41 |
| Mirtazapine | Mirtazapine | 53 | 11 |
| Baclofen | Baclofen | 52 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 29 |
| Alendronate Sodium | Alendronate Sodium | 49 | 17 |
| Topiramate | Topiramate | 48 | 11 |
| Ezetimibe | Ezetimibe | 47 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 47 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 47 | 14 |
| Promethazine Hcl | Promethazine Hcl | 45 | 15 |
| Chlorthalidone | Chlorthalidone | 43 | 15 |
| Bupropion Xl | Bupropion Hcl | 42 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 40 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Linzess | Linaclotide | 36 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 35 | 18 |
| Sildenafil Citrate | Sildenafil Citrate | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Lamotrigine | Lamotrigine | 34 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Lidocaine | Lidocaine | 34 | suppressed |
| Lansoprazole | Lansoprazole | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Fluconazole | Fluconazole | 32 | 25 |
| Sucralfate | Sucralfate | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Nystatin | Nystatin | 28 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 27 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 23 |
| Nitroglycerin | Nitroglycerin | 26 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 14 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Folic Acid | Folic Acid | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 23 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 13 |
| Diazepam | Diazepam | 20 | 12 |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $127.59 · 7 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, CAPLYTA, INSPIRE, Ozempic, Rybelsus, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error